Integral Molecular推出Paratope-PLUS™，一种支持强大专利声明和抗体工程的CDR扫描服务-动脉网

Integral Molecular Launches Paratope-PLUS™, a CDR-Scanning Service to Support Robust Patent Claims and Antibody Engineering

CISION 等信源发布 2025-03-11 20:03



可切换为仅中文







Technology aligns with new USPTO guidance for writing antibody patent claims and enables antibody engineering for novel intellectual property

技术符合美国专利商标局关于撰写抗体专利权利要求的新指南，并有助于为新型知识产权进行抗体工程设计。

PHILADELPHIA

费城

，

March 11, 2025

2025年3月11日

/PRNewswire/ -- Integral Molecular, a leader in antibody discovery and protein engineering, has launched a new technology-based service to strengthen antibody patent claims in response to recent changes in U.S. patent guidelines. Paratope-PLUS™ CDR-scanning uses high-throughput mutagenesis to support antibody patenting strategies and novel claim sets.

/PRNewswire/ -- 作为抗体发现和蛋白质工程领域的领导者，Integral Molecular推出了一项基于新技术的服务，以应对美国专利指南的最新变化，从而加强抗体专利声明。Paratope-PLUS™ CDR扫描利用高通量诱变技术，支持抗体专利策略和新颖的权利要求组合。

Integral Molecular's CDR-scanning strategy is described in the .

Integral Molecular的CDR扫描策略在中有所描述。

February 2025

2025年2月

issue of

问题

Nature Biotechnology

《自然-生物技术》

。

Learn how

学习如何

Paratope-PLUS™

抗原结合位点-PLUS™

CDR-scanning can protect antibody intellectual

CDR扫描可以保护抗体知识产权

property

属性

Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function. This approach broadly defines antibody 'genus' claims around a common structural feature (the paratope, the antibody residues that make direct contact with the target).

Paratope-PLUS™ 包括将抗体的CDR（互补决定区）中的每个残基突变为其他19种氨基酸，识别保留或增强功能的所有变异。这种方法围绕共同的结构特征（即与靶标直接接触的抗体残基，即抗原结合位点）广泛定义了抗体的“属”权利要求。

Importantly, this fulfills U.S. Patent and Trademark Office (USPTO) requirements of .

重要的是，这满足了美国专利商标局 (USPTO) 的要求。

enablement

赋能

(how to make) and

（如何制作）和

written description

书面描述

(demonstration of possession).

（展示占有）。

'The Supreme Court's decision last year to invalidate broad antibody functional claims rewrote the rules for patents, creating an IP dilemma,' said

“去年，最高法院判决无效广泛的抗体功能性专利主张的决定改写了专利规则，造成了一个知识产权困境，”

Benjamin Doranz

本杰明·多兰兹

, CEO of Integral Molecular

，Integral Molecular首席执行官

. 'With our 20 years of experience in high-throughput protein mutagenesis and antibody characterization, we are excited to offer a solution that can provide strong protection for antibody intellectual property and insights to create better therapeutics.'

“凭借我们在高通量蛋白质诱变和抗体特性方面的20年经验，我们很高兴提供一种能够为抗体知识产权提供有力保护并为创造更好的治疗药物提供见解的解决方案。”

Paratope-PLUS™ provides:

Paratope-PLUS™ 提供：

Expression and binding data for every antibody variant

每个抗体变体的表达和结合数据

A genus of structurally related antibodies that meet enablement and written description requirements for broad patent claims

一个在结构上相关的抗体属，满足广泛专利权利要求的可实施性和书面描述要求。

Data describing variants with improved expression, binding, and developability, providing the basis for antibody engineering and novel claims

描述具有改进表达、结合和可开发性的变异体的数据，为抗体工程和新主张提供了基础。

Antibody developers interested in discussing CDR-scanning should

对讨论CDR扫描感兴趣的抗体开发者应

contact Integral Molecular

联系Integral Molecular

About Integral Molecular

关于Integral Molecular

Integral Molecular (

积分分子 (

integralmolecular.com

积分分子.com

) is the industry leader in creating transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on antibodies, membrane proteins, and viruses, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses..

）是创造推动针对难以处理的蛋白质靶标治疗发现的变革性技术的行业领导者。Integral Molecular凭借20多年专注于抗体、膜蛋白和病毒的经验，其技术已被整合到600多家生物技术和制药公司的药物发现流程中，助力发现癌症、糖尿病、自身免疫疾病以及诸如SARS-CoV-2、埃博拉、寨卡和登革热等病毒威胁的新疗法。

Follow Integral Molecular on

关注Integral Molecular

领英

Press Contact

媒体联系

Integral Molecular

积分分子

Soma Banik, PhD, Director of Public Relations

索马·巴尼克博士，公共关系总监

info@integralmolecular.com

Banik

班尼克